ADAR1 Capital Management LLC Trims Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

ADAR1 Capital Management LLC trimmed its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 95.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,963 shares of the biopharmaceutical company's stock after selling 1,046,703 shares during the period. ADAR1 Capital Management LLC's holdings in Royalty Pharma were worth $1,275,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Swedbank AB raised its holdings in shares of Royalty Pharma by 10.3% in the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock valued at $310,308,000 after purchasing an additional 1,136,800 shares in the last quarter. State Street Corp increased its holdings in Royalty Pharma by 0.3% in the third quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company's stock valued at $269,215,000 after buying an additional 29,451 shares during the last quarter. Geode Capital Management LLC raised its stake in Royalty Pharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock valued at $186,846,000 after buying an additional 46,765 shares in the last quarter. Norges Bank purchased a new stake in Royalty Pharma during the 4th quarter worth about $124,498,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after acquiring an additional 130,025 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Performance

NASDAQ:RPRX traded up $0.74 during mid-day trading on Friday, reaching $31.95. 5,897,307 shares of the stock were exchanged, compared to its average volume of 3,242,342. The stock has a market capitalization of $18.42 billion, a P/E ratio of 22.03, a P/E/G ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a 50 day simple moving average of $32.50 and a 200-day simple moving average of $29.14. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on RPRX. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.